
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter D - Drugs for Human Use
#### PART 312 - INVESTIGATIONAL NEW DRUG APPLICATION
##### Subpart B - Investigational New Drug Application (IND)
###### ยง 312.30 Protocol amendments.
####### b

(iii) In the case of a new investigator, the investigator's name, the qualifications to conduct the investigation, reference to the previously submitted protocol, and all additional information about the investigator's study as is required under ยง 312.23(a)(6)(iii)().

(2) Reference, if necessary, to specific technical information in the IND or in a concurrently submitted information amendment to the IND that the sponsor relies on to support any clinically significant change in the new or amended protocol. If the reference is made to supporting information already in the IND, the sponsor shall identify by name, reference number, volume, and page number the location of the information.

(3) If the sponsor desires FDA to comment on the submission, a request for such comment and the specific questions FDA's response should address.
